Kyle Platz, DO
Family Medicine · Manhattan, KSNPI 1932223690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,450 of the $51,268 with a category attached, or 80.8%. GSK accounts for 84.8% of it on its own, with 54 other manufacturers making up the rest. Reporting peaked in 2022 at $19,227 and has fallen 92.6% since, to $1,419 in 2025. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $93.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$43K
- Lilly USA, LLC$1K
- Novo Nordisk$827
- AbbVie$797
- Pfizer$613
- Amgen$452
- plus $4K from 49 others
What the payments were for
- Speaking & faculty fees$41,45081%
- Travel & lodging$1,1022%
- Food & beverage$8,71617%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$33,695
- AREXVY$1,250
- ANORO ELLIPTA$900
How this compares
$51,268 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $49,388 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $41,618 |
| EliquisApixaban | 48 | $39,685 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $37,836 |
| JardianceEmpagliflozin | 20 | $30,650 |
| FarxigaDapagliflozin Propanediol | 26 | $24,957 |
| TrulicityDulaglutide | 19 | $23,898 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 65 | $19,571 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,937 |
| Praluent PenAlirocumab | 13 | $7,613 |
| XareltoRivaroxaban | 11 | $6,108 |
| Repatha SyringeEvolocumab | 11 | $6,076 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 25 | $5,315 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,639 |
| Nebivolol Hcl | 24 | $2,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix | $43,475 | $74,441137 claims |
| Novo NordiskOzempic | $827 | $49,38841 claims |
| PfizerEliquis, Paxlovid | $613 | $41,11461 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $60 | $37,83642 claims |
| Boehringer IngelheimJardiance | $355 | $30,65020 claims |
| AstraZenecaFarxiga | $335 | $24,95726 claims |
| Lilly USA, LLCTrulicity | $1,125 | $23,89819 claims |
| Johnson & JohnsonXarelto | $97 | $6,10811 claims |
| AbbVieSynthroid | $797 | $1,05911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Manhattan
- Bradley HarrisonManhattan$314K
- Kent KiracofeManhattan$189K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.